Prostate Supplement Gains U.S. Patent

LOS ANGELESOncoNatural Solutions has been awarded a U.S. patent for its PHC® (Prostate Health Cocktail), a dietary supplement that contains saw palmetto, selenium, lycopene and other vitamin, mineral and specialty ingredients. The patent (US #8,221,803) was based on results from an FDA-approved clinical study showing the supplement stabilized or reduced prostate specific antigen (PSA) in men with recurrent prostate cancer.

Presented at the American Society of Clinical Oncology (ASCO) 2012 Genitourinary Cancers Symposium, San Francisco, the research found 83 percent of patients with recurrent prostate cancer who took three PHC capsules each day showed stabilized PSA levels. In almost 30 percent of the same study population, PSA declined. The researchers noted testosterone did not significantly decrease in this group, ruling out erectile dysfunction (ED) as a side effect of PHC supplementation. OncoNatural noted while the study provides clear evidence PHC is beneficial to men with recurrent prostate cancer, the supplement may also contribute to healthy outcomes for men diagnosed with enlarged prostate or early prostate disease.

The PHC formula was developed by oncologist and prostate cancer researcher Jacek Pinski, M.D., Ph.D., and contains minerals, herbs, vitamins and isoflavanoids shown to reduce the risk of prostate disease in men ages 40 and olderEGCG from green tea extract, along with selenium, lycopene, genistein, daidzein, vitamin D3, vitamin E and saw palmetto fruit extract. The company said the supplement has proven to be particularly effective at relieving the discomfort and frustration of urinary problems and ED.

"PHC is designed for use as a complement to existing prostate cancer treatments," Dr. Pinski stated. "The formula is based on extensive research, and evidence of its effectiveness continues to accumulate. The recent patent award reinforces the promise of this breakthrough dietary supplement and our commitment to forward-thinking treatment plans for men with recurrent prostate cancer."